Feature | May 14, 2014

Study Shows Significant Overall Cost Savings Using Quadripolar System

Comparative effectiveness study shows use of quadripolar technology reduces hospital utilization and lowers overall costs

May 14, 2014 — Data presented during Heart Rhythm 2014 found the use of quadripolar leads reduced the number of hospitalizations by 53 percent when compared to the non-quadripolar group. This hospitalization rate reduction translated into a statistically significant 62 percent reduction in overall costs for both healthcare systems and patients.

The “Hospitalization Rates and Associated Cost Analysis of Quadripolar versus Bipolar CRT-D: a comparative analysis of a single-center prospective Italian registry” presentation included data that demonstrated hospitalization rates for the quadripolar group were lower than the non-quadripolar group, and patients with the St. Jude Medical Quartet quadripolar LV (left ventricular) lead had a 98 percent probability of having lower costs than patients with non-quadripolar leads. The study showed that use of the quadripolar LV lead was associated with significantly reduced hospitalizations specific to the two types of hospitalizations studied: heart failure and LV lead surgical revision.

“These data are compelling evidence as they show a significant cost saving for the healthcare system and patients utilizing the St. Jude Medical quadripolar pacing system,” said Giovanni Forleo, M.D., electrophysiologist at the University Hospital of Tor Vergata in Rome. “This study showed a strong cost benefit, further demonstrating why quadripolar technology is becoming the standard-of-care for patients requiring CRT [cardiac resynchronization therapy].”

The prospective, single-center, observational registry was a first-time evaluation of hospitalization rates and cost reduction following CRT with quadripolar versus non-quadripolar LV leads. Over three years, 198 patients implanted with either a St. Jude Medical Quartet quadripolar LV lead or a non-quadripolar LV lead, were enrolled in the study. The goal of the study was to compare the hospitalization rate related to heart failure and LV lead surgical revisions between the Quartet quadripolar lead and a traditional bipolar lead for cardiac resynchronization therapy defibrillators (CRT-Ds).

“This study provides additional evidence that the quadripolar system improves patient outcomes and reduces healthcare costs,” said Mark D. Carlson, M.D., chief medical officer and vice president of global clinical affairs for St. Jude Medical. “This study is another example of St. Jude Medical’s commitment to investing in disruptive technologies that transform the treatment of expensive epidemic diseases.”

For more information: www.sjm.com

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). CRF sponsors TCT.

The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO).

Feature | Cath Lab| September 12, 2017
September 12, 2017 – The Cardiovascular Research Foundation (CRF) a
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Overlay Init